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Nonischemic dilated cardiomyopathy (NIDCM) is a com-
mon cause of congestive heart failure (CHF) and is a risk
factor for sudden cardiac death (1,2). Although an asymp-
tomatic patient with ischemic cardiomyopathy can now be
approached with a reasonably established strategy (e.g., risk
stratification using an electrophysiologic [EP] study in those
with moderately reduced left ventricular [LV] function and
non-sustained ventricular tachycardia [NSVT] [3]; a pro-
phylactic implantable cardioverter-defibrillator [ICD] in
those with severely reduced LV function [4]), the optimal
management of asymptomatic patients with NIDCM has
been less rigorously defined.
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Inducibility of VT at EP study in these patients correlates
poorly with past or future episodes of VT (5,6). The only
antiarrhythmic drug shown to be of possible use in prevent-
ing ventricular tachyarrhythmias, amiodarone, has not been
evaluated in depth. The often-quoted GESICA study of
empiric amiodarone therapy in dilated cardiomyopathy
(DCM) comprised a very heterogeneous population group,
of which 40% of the patients had ischemic heart disease (7).
In the Survival Trial of Antiarrhythmic Therapy in Con-
gestive Heart Failure (CHF-STAT) (70% of these patients
had ischemic heart disease), amiodarone therapy was asso-
ciated with a trend toward reduced mortality in the non-
ischemic cardiomyopathy group (8).
The only published randomized trial employing ICDs for
primary prophylaxis of sudden cardiac death in patients with
NIDCM studied 104 asymptomatic patients with a recent
onset of NIDCM (9 months) (the Cardiomyopathy Trial
[CAT]). Patients were randomized to ICD or control, and
cumulative survival at four years was 86% and 80%, respec-
tively (p  ns) (9).
In this issue of the Journal, Strickberger et al. (10) results
of a randomized multicenter trial, Amiodarone versus Im-
plantable Defibrillator Randomized Trial (AMIOVIRT), in
patients with NIDCM and asymptomatic NSVT are re-
ported. One hundred and three patients with NIDCM and
asymptomatic NSVT (no prior syncope, sustained VT, or
sudden death) were randomized to either amiodarone (52
patients) or ICD (51 patients). The study was terminated at
interim analysis because of lower than expected mortality.
Analysis of outcomes by intention to treat found that
survival at three years was approximately 88%, with no
significant difference between the groups assigned to either
initial amiodarone or ICD therapy. A trend toward lower
initial cost and improved arrhythmia-free survival was noted
in the amiodarone group.
Before generalizing the results of AMIOVIRT as a
therapeutic strategy, one must consider all features of the
patient population as well as the design of the study, which
is the focus of this editorial.
First, the significance of NSVT in these patients still
remains unclear as a risk marker of future arrhythmic events.
The prevalence of NSVT in patients with DCM is high
(50%) (9,11), and while some studies have found this to
be a marker of high risk of death (12), others have not (11).
In the recent CAT study, survival was no different in
patients with NSVT from those without NSVT (9). Even
the prognosis of rapid (220/min) polymorphic “bursts” or
monomorphic episodes that last 20 to 25 s is not clearly
determined. Thus clinically, it is has been difficult to
establish a level of risk according to the presence or type of
NSVT.
Second, patients with NIDCM form an extremely het-
erogeneous group. The present study appeared to include all
forms of NIDCM. The risk of sudden death could be
different in those with DCM caused by sarcoidosis (13) or
hypertrophic cardiomyopathy (14) from such risk in those
whose DCM is, for example, “idiopathic/post viral,” hyper-
tensive, or alcoholic. The CAT study that found no benefit
for ICDs was comprised largely of patients with idiopathic
DCM (9).
Third, the mortality rate was significantly lower in these
recent NIDCM studies than previously reported. Whereas
previous studies noted NIDCM mortality rates as high as
31% within one year (15), patients in AMIOVIRT had a
mortality of 10% at one year and 12% to 13% at three
years. This low mortality rate was observed despite the likely
inclusion of patients referred to tertiary care centers, who
traditionally have a higher mortality than community-based
patients (15). It is reasonable to assume that this is largely
due to the dramatic effect of treatment with angiotensin-
converting enzyme (ACE) inhibitor therapy and other
drugs. This reduced mortality, however, raises the issue of
what the true mortality rate is in patients currently treated
with optimal medical therapy. In AMIOVIRT, approxi-
mately 50% of the patients were receiving beta-blockers in
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addition to ACE inhibitors at final follow-up. Because the
trial began in 1996, it is possible that beta-blocker use was
lower earlier in the trial. It is likely that more widespread
beta-blocker usage would have provided an incremental
benefit to ACE inhibitors in this population, possibly
reducing mortality rates further.
Bradycardia has long been implicated as a cause of
mortality in patients with CHF. A telemetry study of
patients admitted with advanced CHF found that all pa-
tients with NIDCM in fact died with bradycardia (sinus
bradycardia, AV block, pulseless electrical activity), whereas
all those who suffered VT/VF as the terminal event had
ischemic DCM (16). One indirect inference that may be
drawn from the present study is that “backup ventricular
pacing” to prevent death from bradyarrhythmia may not
influence mortality outcome in NIDCM, because mortality
rates were similar in the amiodarone arm and the
implanted-device arm.
Nevertheless, the overall effect of implanted device ther-
apy on mortality due to CHF (non-arrhythmic mortality) in
patients with NIDCM is unknown. Although it is counter-
intuitive to think that an ICD could worsen survival, a
population that has a relatively low incidence of sudden
death might be significantly affected by any intervention
that worsens LV “pump function.” At the present time the
effect of right ventricular pacing (automatic cardiac desyn-
chronization) from a prophylactic ICD in this population is
not well defined. In patients with ischemic cardiomyopathy,
prophylactic ICD insertion appeared to result in a slightly
higher rate of hospital admissions for CHF (4). The advent
of biventricular pacing is likely to influence the natural
clinical history of these patients further and may favorably
modify our ability to use beta blockers and ACE inhibitors
aggressively.
Thus, at the present time, while improbable, it is unclear
whether medical therapy with widespread use of beta-
blockers, spironolactone, and ACE inhibitors results in a
lower total mortality rate than either amiodarone or pro-
phylactic ICD. In addition, widespread adoption of a
strategy using amiodarone in these asymptomatic patients
may be a futile exercise, granted the relatively high rate of
discontinuation of amiodarone in this trial (25 of 52
patients; almost 50%) in the amiodarone arm.
Despite these issues, the present study highlights the
contrast of disease substrate between ischemic and
NIDCM, and in concert with CAT (9), raises the possibil-
ity that prophylactic ICD implantation in asymptomatic
patients with NIDCM may be futile.
This is in sharp contrast to patients with NIDCM who
have either syncope or an aborted sudden cardiac death.
Patients with unexplained syncope who undergo ICD im-
plantation experience a rate of resuscitative shocks by the
ICD similar to patients who undergo implantation for
cardiac arrest (17). From meta-analysis of Antiarrhythmics
Versus Implantable Defibrillators (AVID), Cardiac Arrest
Study Hamburg (CASH), and Canadian Implantable De-
fibrillator Study (CIDS) data, sudden death/symptomatic
VT survivors with NIDCM have a similar rate of recurrence
of sudden death as patients with ischemic cardiomyopathy
and thus a similar benefit (18). Therefore, the weight of
evidence is in favor of implantation of ICDs in patients who
have any form of DCM and either unexplained syncope or
aborted sudden death.
One non-invasive test that appears to show promise in
the risk stratification of NIDCM is T-wave alternans
(TWA). The negative predictive value of TWA is high, and
in concert with ejection fraction, specific features of TWA
such as a low onset heart rate of TWA can be predictive of
future cardiac events (19). One potential strategy in the
asymptomatic patient with NIDCM might be to assign
TWA negative patients to “best medical” CHF therapy and
TWA positive patients to that plus amiodarone therapy.
Naturally, this must be tested prospectively.
Despite these criticisms, the authors of the present study
should be commended for their efforts in clarifying rational
therapy for patients with NIDCM. At the present time,
when confronted with a patient who fits this study profile,
we believe that our existing position would be not to
empirically implant an ICD, and this study confirms that
this strategy is reasonable. It is probably also reasonable to
offer amiodarone therapy with the understanding that this is
a strategy unproven to be superior to usual medical therapy
(beta-blockers, ACE inhibitors). For a more definitive
approach in managing these patients, we await further
clinical trial data, including that from Sudden Cardiac
Death in Heart Failure Trial (SCD-HEFT).
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